In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs. Tanner M. Ann Intern Med 2021 Jun 1. doi: 10.7326/ACPJ202106150.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tanner M. In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs. Ann Intern Med 2021 Jun 1. doi: 10.7326/ACPJ202106150.
PMID: 34058114